Table 1.
The clinicopathological characteristics of the patients included in this study
| Sample ID | Sex | Age | Tumor type | KNOSP grade | Tumor dimension | Immunohistochemistry (% of stained cells) | Detailed pathological description | |||
|---|---|---|---|---|---|---|---|---|---|---|
| TP53 | MIB1 | MGMT | MCM7 | |||||||
| 1 | F | 33 | Crooke’s cell adenoma | 0 | Microadenoma | 1 | 3 | 75 | 20 focally: 50 | Crooke‘s cell variant, atypical |
| 2 | M | 49 | Crooke’s cell adenoma | 4 | Macroadenoma | 1 | 1 | 0 | 50 | Crooke‘s cell variant |
| 3a | F | 55 | Crooke’s cell adenoma | 4 | Macroadenoma | 3 | 3 | 0 | 30 | Crooke‘s cell variant, atypical |
| 3b | F | 56 | Crooke’s cell adenoma | 4 | Macroadenoma | 10 | 10 | 10 | 40 | Crooke‘s cell variant, atypical |
| 4 | F | 33 | Crooke’s cell adenoma | 0 | Microadenoma | 3 | 3 | 90 | 20 focally: 80 | Crooke’s cell variant, atypical |
| 5 | F | 74 | Invasive PA | 3 | Macroadenoma | 1 | 3 | 90 | 20 | SG-ACTH, atypical, single mitotic figures |
| 6 | F | 48 | Invasive PA | 3 | Macroadenoma | 0 | 3 | N/A | 10 | DG-ACTH |
| 7a | M | 55 | Invasive PA | 3 | Macroadenoma | N/A | N/A | N/A | N/A | SG-ACTH |
| 7b | M | 55 | Invasive PA | 3 | Macroadenoma | 50 | 20 | 0 | 30 | SG-ACTH, atypical |
| 8 | F | 59 | Invasive PA | 2 | Macroadenoma | 0 | 3 | 0 | 10 | SG-ACTH |
| 9 | F | 36 | Invasive PA | 4 | Macroadenoma | 2 | 20 | 70 | 40 focally: 60 | DG-ACTH, atypical |
| 10 | F | 66 | Invasive PA | 4 | Macroadenoma | 2 | 5 | 50 | 50 | SG-ACTH, atypical |
| 11 | M | 61 | Invasive PA | 4 | Macroadenoma | 25 | 5 | 20 | 30 | SG-ACTH, atypical, nuclear atypia |
| 12 | F | 17 | Invasive PA | 3 | Macroadenoma | 3 | 3 | 90 | 10 | SG-ACTH, high nuclear atypia |
| 13 | F | 78 | Invasive PA | 4 | Macroadenoma | 1 | 1 | 90 | 5 focally: 30 | DG-ACTH |
| 14 | F | 58 | Invasive PA | 2 | Macroadenoma | 0 | 3 | 100 | 50 | DG-ACTH, atypical |
| 15 | F | 43 | Invasive PA | 2 | Macroadenoma | 1 | 3 | 100 | 20 | DG-ACTH, atypical |
| 16 | F | 44 | Invasive PA | 2 | Microadenoma | 1 | 3 | 30 | 15 | DG-ACTH |
| 17 | F | 58 | Noninvasive PA | 1 | Macroadenoma | 1 focally: 20 | 1 | 90 | 1 focally: 20 | – |
| 18 | M | 49 | Noninvasive PA | 0 | Microadenoma | 0 | 1 | 50 | 5 | DG-ACTH |
| 19 | F | 21 | Noninvasive PA | 0 | Microadenoma | 1 | 3 | 0 | 5 | – |
| 20 | F | 51 | Noninvasive PA | 0 | Microadenoma | 1 | 1 | 90 | 1 | SG-ACTH, alpha(+/−) |
| 21 | F | 42 | Noninvasive PA | 0 | Microadenoma | 1 | 1 | 70 | 20 focally: 80 | DG-ACTH |
| 22 | F | 36 | Noninvasive PA | 0 | Microadenoma | 0 | 1 | 50 | 1 | DG-ACTH |
| 23 | F | 44 | Noninvasive PA | 1 | Microadenoma | 1 | 1 | 100 | 3 | DG-ACTH |
| 24 | F | 34 | Noninvasive PA | 0 | Microadenoma | 20 | 3 | 90 | N/A | DG-ACTH, atypical |
| 25 | M | 34 | Noninvasive PA | 1 | Macroadenoma | 2 | 3 | 50 | 30 | DG-ACTH |